Found: 9
Select item for more details and to access through your institution.
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 121, doi. 10.1002/hon.3163_82
- By:
- Publication type:
- Article
A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 562, doi. 10.1002/hon.3164_421
- By:
- Publication type:
- Article
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIAL.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 77, doi. 10.1002/hon.3163_41
- By:
- Publication type:
- Article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
- By:
- Publication type:
- Article
Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 428, doi. 10.1002/hon.3164_315
- By:
- Publication type:
- Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.57_2880
- By:
- Publication type:
- Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.22_2880
- By:
- Publication type:
- Article
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.157_2880
- By:
- Publication type:
- Article
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study.
- Published in:
- 2020
- By:
- Publication type:
- journal article